The role of the intestinal microbiome in Crohn's disease (CD) treatment remains poorly understood. This study investigates microbe-host interactions in CD patients undergoing ustekinumab (UST) therapy. Fecal metagenome, metabolome, and host transcriptome data from 85 CD patients were analyzed using multi-omics integration and mediation analysis. Our findings reveal significant microbiome-metabolite-host interactions. Specifically, Faecalibacterium prausnitzii was linked to altered L-ornithine biosynthesis, resulting in higher L-ornithine levels in patients before UST therapy. In vivo and in vitro studies demonstrated that microbiome-derived L-ornithine enhances UST treatment sensitivity in CD by disrupting the host IL-23 receptor signaling and inhibiting Th17 cell stabilization through the IL-12RB1/TYK2/STAT3 axis. L-ornithine significantly enhances the therapeutic efficacy of UST in CD patients, as demonstrated in a prospective clinical trial. These findings suggest that targeting specific microbe-host metabolic pathways may improve the efficacy of inflammatory bowel disease (IBD) treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cmet.2025.01.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Examining the Accuracy and Reproducibility of Responses to Nutrition Questions Related to Inflammatory Bowel Disease by Generative Pre-trained Transformer-4.
Crohns Colitis 360
January 2025
Department of Medicine, Karsh Division of Digestive and Liver Diseases, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: Generative pre-trained transformer-4 (GPT-4) is a large language model (LLM) trained on a vast corpus of data, including the medical literature. Nutrition plays an important role in managing inflammatory bowel disease (IBD), with an unmet need for nutrition-related patient education resources. This study examines the accuracy, comprehensiveness, and reproducibility of responses by GPT-4 to patient nutrition questions related to IBD.
View Article and Find Full Text PDFPatient experiences with and adherence to Crohn's disease exclusion diet in Dutch Crohn's disease patients: a cohort study.
Therap Adv Gastroenterol
March 2025
Department of Nutrition and Dietetics, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Background: Dietary therapy is commonly used as a treatment for Crohn's disease (CD). High dietary adherence is associated with achieving clinical remission. Crohn's disease exclusion diet (CDED) is a relatively new therapy in the management of CD.
View Article and Find Full Text PDFMyositis of pterygoid muscles and superior ophthalmic vein and cavernous sinus thrombosis in active Crohn's disease undergoing ustekinumab treatment: a case report and literature review.
Front Pharmacol
February 2025
Department of Pediatric Gastroenterology and Hepatology and nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Introduction: Myositis is a rare extra-intestinal presentation in patients with inflammatory bowel diseases (IBD), and its occurrence has only been described in a few case reports. However, it is essential to consider other potential causes as patients with IBD are more susceptible to infections due to their immunocompromised status, which may also be exacerbated by immunosuppressive drugs contributing to myositis. Our case highlights the complexity and challenges in diagnosing and managing myositis in patients with IBD as well as a review of the literature.
View Article and Find Full Text PDFNovel Outcomes in Inflammatory Bowel Disease.
J Crohns Colitis
March 2025
Takeda Pharmaceuticals, Inc., Cambridge, MA, USA (at the time of the analyses).
Inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are lifelong chronic, relapsing and remitting conditions that culminate in disease progression in many patients. Effective management of CD and UC requires consideration of both short and long-term treatment outcomes. Historically, short-term outcomes such as clinical and endoscopic remission and symptom relief have been evaluated in clinical trials.
View Article and Find Full Text PDFEditorial: Upadacitinib-A Promising Induction Agent for Paediatric Crohn's Disease?
Aliment Pharmacol Ther
March 2025
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Children's Hospital Western Ontario, Western University, London Health Sciences Centre, London, Ontario, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!